Therapeutic Response

EGFR TKD activating variants status confers therapeutic sensitivity to Gefitinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Iressa (gefitinib) [product monograph]. HC. Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK